STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4159 by analyst upside · 2026-06-27
TWST
Twist Bioscience Corporation
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
-25.8%
implied upside to consensus target
Current Price $99.84
Consensus Target $74.1
Bull Target $95.0
Bear Target $36.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
2
Sell
0
52-Week Low $23.3
52-Week High $104.23
YTD Return +208.2%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E -130.8x
EPS (TTM) $-1.37
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $409M
Profit Margin -19.8%
52-WEEK RANGE
52-Week Low $23.3
52-Week High $104.23
Current Price $99.84
Bear Target $36.0
Bull Target $95.0
● Now $99.84 ● Target $74.1
TRADING DATA
Avg Volume 1.6M
YTD Return +208.2%
Analyst Count 10
Consensus Buy
Upside to Target -25.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Twist Bioscience Corporation (TWST) is currently trading at $99.84 with a Wall Street consensus price target of $74.1, which is 25.8% below the current price over the next 12 months. 10 analysts currently cover TWST, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $95.0, while the most cautious has a target of $36.0.

TWST operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 208.2% year-to-date and is currently trading near the upper end of its 52-week range of $23.3 – $104.23.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TWST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen — Reiterated
Buy → Buy 2026-06-15 Building track record
Canaccord Genuity ● Initiated
Buy 2026-06-15 Building track record
Piper Sandler ● Initiated
Overweight → Overweight 2026-06-11 14% win rate (7 calls)
Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-05-05 29% win rate (7 calls)
Barclays — Reiterated
Overweight → Overweight 2026-05-05 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-05 62% win rate (8 calls)
Baird — Reiterated
Outperform → Outperform 2026-05-05 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-04-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
18/30
Consensus clarity
18/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →